Current perspectives of bispecific antibody-based immunotherapy |
| |
Authors: | Talac R Nelson H |
| |
Affiliation: | Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota 55902, USA. |
| |
Abstract: | The field of bispecific antibodies is an evolving field of research that has increasing clinical appeal.The fusion of two antibodies or antibody fragments introduced a new way to override natural specificity of T cell and induce effector responses against tumor targets in MHC-unrestricted manner. Initial experiences with bispecific antibodies demonstrate both the promise for and limitations of this anti-cancer strategy. Significant body of work has shown that bispecific antibodies have potential to induce T cell mediated anti-tumor responses in pre-clinical models. However, immunotherapy with bispecific antibodies in humans has yet to prove its value in clinical settings. In addition, the production of high-quality bispecific antibodies for clinical applications, the optimal size and avidity of bispecific antibodies, and in vivo T cell pre-activation remain critical issues. In this review, we summarize recent progress in bispecific antibody-based immunotherapy and address essential aspects of this anti-cancer strategy. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|